References

medsovet

Медицинский Совет

Meditsinskiy sovet = Medical Council

2079-701X2658-5790

REMEDIUM GROUP Ltd.

10.21518/2079-701X-2016-11-42-47

medsovet-1539

Research Article

НЕРВНО-ПСИХИЧЕСКИЕ РАССТРОЙСТВА

NEUROPSYCHIATRIC DISORDERS

НАРУШЕНИЯ СНА КАК МЕЖДИСЦИПЛИНАРНАЯ ПРОБЛЕМА

SLEEP DISORDERS: AN INTERDISCIPLINARY PROBLEM

ЯКУПОВ

Э. Я.

YAKUPOV

E. Y.

д.м.н., профессор

MD, Prof.

Казанский государственный медицинский университет Минздрава РоссииРоссияKazan State Medical University, MoH RFRussian Federation

2016

30122016

0114247

2016

ЯКУПОВ Э.Я.

YAKUPOV E.Y.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.med-sovet.pro/jour/article/view/1539

Инсомния представляет собой расстройство, которое значительно снижает качество жизни, влияет на работоспособность, обучаемость, может приводить к социальной дезадаптации, личностным изменениям, а также связано с рядом метаболических нарушений. Подчеркивается важность междисциплинарного подхода к лечению инсомнических расстройств, обсуждаются принципы использования снотворных препаратов для коррекции нарушений сна. Приводятся результаты применения мелатонина у 2 062 пациентов в возрасте 45–70 лет.

Insomnia is a sleep disorder that significantly reduces the quality of life, affects performance, learning ability, may lead to social maladjustment, personality changes, and is associated with a number of metabolic disorders. The article emphasizes the importance of an interdisciplinary approach to the treatment of sleep disorders, discusses administration of sleeping pills to manage sleep disorders.

нарушения снаинсомниялечениемелатонин

sleep disordersinsomniatreatmentmelatonin

References1

Morin CM, Hauri PJ, Espie CA, Spielman AJ, Buysse DJ, Bootzin RR. Nonpharmacologic treatment of chronic insomnia: an American Academy of Sleep Medicine review. Sleep, 1999, 22: 1134-56.

Costa e Silva JA, Chase M, Sartorius M, Roth T. Special report from a symposium held by the World Health Organization and the World Federation of Sleep Research Societies: an overview of insomnias and related disorders – recognition, epidemiology, and rational management. Sleep, 1996, 19: 412-6.

The international classification of sleep disorders, revised: diagnostic and coding manual. Rochester, Minn.: American Sleep Disorders Association, 1997.

Morin CM, Culbert JP, Schwartz SM. Nonpharmacological interventions for insomnia: a meta–analysis of treatment efficacy. Am J Psychiatry, 1994, 151: 1172-80.

Spielman AJ, Caruso LS, Glovinsky PB.A behavioral perspective on insomnia treatment. Psychiatr Clin North Am, 1987, 10: 541-53.

Littner M, Hirshkowitz M, Kramer M, et al. Practice parameters for using polysomnography to evaluate insomnia: an update. Sleep, 2003, 26: 754-60.

The international classification of sleep disorders: diagnostic & coding manual, ICDS-2. 2nd ed. Westchester, Ill.: American Academy of Sleep Medicine, 2005.

Perlis ML, Smith MT, Pigeon WR. Etiology and pathophysiology of insomnia. In: KrygerMH, RothT, Dement WC, eds. Principles and practice of sleep medicine. 4th ed. Philadelphia: Elsevier/Saunders, 2005: 714-25.

Bootzin RR, Epstein D, Wood JM. Stimulus control instructions. In: Hauri PJ, ed. Case studies in insomnia. New York: Plenum Medical Book, 1991: 19-28.

Spielman AJ, Saskin P, Thorpy MJ. Treatment of chronic insomnia by restriction of time in bed. Sleep, 1987, 10: 45-56.

Hauri PJ. Sleep hygiene, relaxation therapy, and cognitive interventions. In: Hauri PJ, ed. Case studies in insomnia. New York: Plenum Medical Book, 1991: 65-84.

Murtagh DRR, Greenwood KM. Identifying effective psychological treatments for insomnia: a meta-analysis. J Consult Clin Psychol, 1995, 63: 79-89.

Espie CA, Inglis SJ, Tessier S, Harvey L. The clinical effectiveness of cognitive behaviour therapy for chronic insomnia: implementation and evaluation of a sleep clinic in general medical practice. Behav Res Ther, 2001, 39: 4-60.

Edinger JD, Wohlgemuth WK, Radtke RA, Marsh GR, Quillian RE. Cognitive behavioral therapy for treatment of chronic primary insomnia: a randomized controlled trial. JAMA, 2001, 285: 1856-64.

Turner RM, Ascher LM. Therapist factor in the treatment of insomnia. Behav Res Ther, 1982, 20: 33-40.

Morgan K, Dixon S, Mather N, Thompson J, Tomeny M. Psychological treatment for insomnia in the management of long-term hypnotic drug use: a pragmatic randomised controlled trial. Br J Gen Pract, 2003, 53: 923-8.

Baillargeon L, Demers L, Ladouceur R. Stimulus–control: nonpharmacologic treatment for insomnia. Can Fam Physician, 1998, 44: 73-9.

Edinger JD, Sampson WS. A primary care «friendly» cognitive behavioral insomnia therapy. Sleep, 2003, 26: 177-82.

Riedel BW, Lichstein KL, Dwyer WO. Sleep compression and sleep education for older insomniacs: self-help versus therapist guidance. Psychol Aging, 1995, 10: 54-63.

Mimeault V, Morin CM. Self-help treatment for insomnia: bibliotherapy with and without professional guidance. J Consult Clin Psychol, 1999, 67: 511-9.

Meoli AL, Rosen CL, Kristo D, et al. Oral nonprescription treatment for insomnia: an evaluation of products with limited evidence. J Clin Sleep Med, 2005, 1: 173-87.

Rogers NL, Dinges DF, Kennaway DJ, Dawson D. Potential action of melatonin in insomnia. Sleep, 2003, 26: 1058-9.

Nowell PD, Mazumdar S, Buysse DJ, Dew MA, Reynolds CF III, Kupfer DJ. Benzodiazepines and zolpidem for chronic insomnia: a meta–analysis of treatment efficacy. JAMA, 1997, 278: 2170-7.

Holbrook AM, Crowther R, Lotter A, Cheng C, King D. Meta–analysis of benzodiazepine use in the treatment of insomnia. CMAJ, 2000, 162: 225-33.

Elie R, Ruther E, Farr I, Elilien G, Salinas E. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. J Clin Psychiatry, 1999, 60: 536-44.

Walsh JK, Vogel GW, Scharf M, et al. A five week, polysomnographic assessment of zaleplon 10 mg for the treatment of primary insomnia. Sleep Med, 2000, 1: 41-9.

Walsh JK, Pollak CP, Scharf MB, Schweitzer PK, Vogel GW. Lack of residual sedation following middle-of-the-night zaleplon administration in sleep maintenance insomnia. Clin Neuropharmacol, 2000, 23: 17-21.

Krystal AD, Walsh JK, Laska E, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, doubleblind, placebo-controlled study of adults with chronic insomnia. Sleep, 2003, 26: 793-9.

Walsh JK, Roth T, Randazzo A, et al. Eight weeks of non-nightly use of zolpidem for primary insomnia. Sleep, 2000, 23: 1087-96.

Perlis ML, McCall WV, Krystal AD, Walsh JK. Long-term, non-nightly administration of zolpidem in the treatment of patients with primary insomnia. J Clin Psychiatry, 2004, 65: 1128-37.

Voshaar RC, van Balkom AJ, Zitman FG. Zolpidem is not superior to temazepam with respect to rebound insomnia: a controlled study. Eur Neuropsychopharmacol, 2004, 14: 301-6.

Vogel GW, Morris D. The effects of estazolam on sleep, performance, and memory: a longterm sleep laboratory study of elderly insomniacs. J Clin Pharmacol, 1992, 32: 647-51.

Roth T, Roehrs TA. A review of the safety profiles of benzodiazepine hypnotics. J Clin Psychiatry, 1991, 52(Suppl): 38-41.

Monti JM, Attali P, Monti D, Zipfel A, de la Giclais B, Morselli PL. Zolpidem and rebound insomnia – a double-blind, controlled polysomnographic study in chronic insomniac patients. Pharmacopsychiatry, 1994, 27: 166-75.

Soldatos CR, Dikeos DG, Whitehead A. Tolerance and rebound insomnia with rapidly eliminated hypnotics: a meta-analysis of sleep laboratory studies. Int Clin Psychopharmacol, 1999, 14: 287-303.

Greenblatt DJ, Harmatz JS, Zinny MA, Shader RI. Effect of gradual withdrawal on the rebound sleep disorder after discontinuation of triazolam. N Engl J Med, 1987, 317: 722-8.

ScharfMB, Roth T, Vogel GW, Walsh JK. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry, 1994, 55: 192-9.

Rothschild AJ. Disinhibition, amnestic reactions, and other adverse reactions secondary to triazolam: a review of the literature. J Clin Psychiatry, 1992, 53(Suppl): 69-79.

Roth T, Hartse KM, Saab PG, Piccione PM, Kramer M. The effects of flurazepam, lorazepam, and triazolam on sleep and memory. Psychopharmacology (Berl), 1980, 70: 231-7.

Canaday BR. Amnesia possibly associated with zolpidem administration. Pharmacotherapy, 1996, 16: 687-9.

Morgenthaler TI, Silber MH. Amnestic sleeprelated eating disorder associated with zolpidem. Sleep Med, 2002, 3: 323-7.

Mendelson WB. Clinical distinctions between long-acting and short-acting benzodiazepines. J Clin Psychiatry, 1992, 53(Suppl): 4-7.

Morin CM, Colecchi C, Stone J, Sood R, Brink D. Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial. JAMA, 1999, 281: 991-9.

Walsh JK, Schweitzer PK. Ten–year trends in the pharmacological treatment of insomnia. Sleep, 1999, 22: 371-5.

Kaynak H, Kaynak D, Gozukirmizi E, GuilleminaultС. The effects of trazodone on sleep in patients treated with stimulant antidepressants. Sleep Med, 2004, 5: 15-20.

Nierenberg AA, Adler LA, Peselow E, Zornberg G, Rosenthal M. Trazodone for antidepressantassociated insomnia. Am J Psychiatry, 1994, 151: 1069-72.

Walsh JK, Erman M, Erwin CW, et al. Subjective hypnotic efficacy of trazodone in DSM3-R primary insomnia. Hum Psycho pharmacol, 1998, 13: 191-8.

Hajak G, Rodenbeck A, Voderholzer U, et al. Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study. J Clin Psychiatry, 2001, 62: 453-63.

Aslan S, Isik E, Cosar B. The effects of mirtazapine on sleep: a placebo controlled, doubleblind study in young healthy volunteers. Sleep, 2002, 25: 677-9.

Hausser-Hauw et al. Effect on sleep architecture and residual effect of a dose of 15 mg of Doxylamine versus triazolam treatment in persistent sleep-onset insomnia. Sep Hop Paris, 1995, 71: no 23-24, 742-750.

Practice Parameters for the Psychological and Behavioral Treatment of Insomnia: An Update. An American Academy of Sleep Medicine Report. Sleep, 2006, 29: 650-9

The authors declare that there are no conflicts of interest present.